Abstract
The 34th annual Advances in Contrast Ultrasound (ACU) International Bubble Conference convened in Chicago, IL, USA, on September 5–6, 2019 to feature new directions of research, preclinical and first-in-man clinical trials, and novel clinical applications highlighting the diversity and utility of contrast enhanced ultrasound (CEUS). An expert group comprising clinicians, engineers, basic scientists, government officials, attorneys, and industry partners convened to collaborate on cutting-edge ultrasound enhancement technology. Utilizing this information, the International Contrast Ultrasound Society (ICUS) continues to have cause to advocate for the safe and appropriate use of CEUS with expanding indications and applications.
Highlights
The conference opened with world-renowned panelists presenting updates on current clinical trials that investigate the important uses of contrast enhanced ultrasound (CEUS), including contrast enhancement and sonoporation via acoustic cavitation
The 34th annual Advances in Contrast Ultrasound (ACU) International Bubble Conference convened in Chicago, IL, USA, on September 5–6, 2019 to feature new directions of research, preclinical and first-in-man clinical trials, and novel clinical applications highlighting the diversity and utility of contrast enhanced ultrasound (CEUS)
The conference opened with world-renowned panelists presenting updates on current clinical trials that investigate the important uses of CEUS, including contrast enhancement and sonoporation via acoustic cavitation
Summary
At 6-month follow-up, patients receiving sonothrombolysis emergently before percutaneous coronary intervention (PCI) were more likely to have decreased infarct size, greater improvement in left ventricular ejection fraction, and decreased rate of implantable cardioverter defibrillator placements compared to those who had not received sonothrombolysis. Given these positive results, this exciting work will continue into the phase as a larger multicenter, multinational trial in the High Ultrasound mechanical index and microbuBBLEs to reduce acute myocardial infarction burden I (HUBBLE-I) study. This provides pathophysiologic and mechanistic insights into understanding the recent discrepant clinical trial results (CoAPT and MitraFR) and an explanation why patients with severe left ventricular dilation and dysfunction appear to experience diminished benefits from the MitraClip procedure, re-emphasizing
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
